Identification of neoantigens for individualized therapeutic cancer vaccines

F Lang, B Schrörs, M Löwer, Ö Türeci… - Nature reviews Drug …, 2022 - nature.com
Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …

Best practices for variant calling in clinical sequencing

DC Koboldt - Genome Medicine, 2020 - Springer
Next-generation sequencing technologies have enabled a dramatic expansion of clinical
genetic testing both for inherited conditions and diseases such as cancer. Accurate variant …

Calling somatic SNVs and indels with Mutect2

D Benjamin, T Sato, K Cibulskis, G Getz, C Stewart… - BioRxiv, 2019 - biorxiv.org
Mutect2 is a somatic variant caller that uses local assembly and realignment to detect SNVs
and indels. Assembly implies whole haplotypes and read pairs, rather than single bases, as …

Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids

KK Dijkstra, CM Cattaneo, F Weeber, M Chalabi… - Cell, 2018 - cell.com
Cancer immunotherapies have shown substantial clinical activity for a subset of patients with
epithelial cancers. Still, technological platforms to study cancer T-cell interactions for …

The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma

CJ Ricketts, AA De Cubas, H Fan, CC Smith, M Lang… - Cell reports, 2018 - cell.com
Renal cell carcinoma (RCC) is not a single disease, but several histologically defined
cancers with different genetic drivers, clinical courses, and therapeutic responses. The …

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

D Chowell, LGT Morris, CM Grigg, JK Weber… - Science, 2018 - science.org
CD8+ T cell–dependent killing of cancer cells requires efficient presentation of tumor
antigens by human leukocyte antigen class I (HLA-I) molecules. However, the extent to …

Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial

JL Vos, B Burman, S Jain, CWR Fitzgerald… - Nature medicine, 2023 - nature.com
Salivary gland cancers (SGCs) are rare, aggressive cancers without effective treatments
when metastasized. We conducted a phase 2 trial evaluating nivolumab (nivo, anti-PD-1) …

[HTML][HTML] Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines

K Ellrott, MH Bailey, G Saksena, KR Covington… - Cell systems, 2018 - cell.com
Summary The Cancer Genome Atlas (TCGA) cancer genomics dataset includes over 10,000
tumor-normal exome pairs across 33 different cancer types, in total> 400 TB of raw data files …

[HTML][HTML] Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for …

MM Li, M Datto, EJ Duncavage, S Kulkarni… - The Journal of molecular …, 2017 - Elsevier
Widespread clinical laboratory implementation of next-generation sequencing–based
cancer testing has highlighted the importance and potential benefits of standardizing the …

Comprehensive and integrated genomic characterization of adult soft tissue sarcomas

AJ Lazar, MD McLellan, MH Bailey, CA Miller… - Cell, 2017 - discovery.ucl.ac.uk
Sarcomas are a broad family of mesenchymal malignancies exhibiting remarkable histologic
diversity. We describe the multi-platform molecular landscape of 206 adult soft tissue …